Gene therapy is a potential new strategy for the treatment of cardiovascular disease. The most efficacious method of gene delivery remains a key hurdle to effective gene therapy. We present the application of a novel, nonviral gene delivery system (TerplexDNA) to augment myocardial transfection. The hearts of New Zealand white rabbits were injected with reporter genes, luciferase cDNA or ␤-galactosidase cDNA, either as naked plasmid DNA or plasmid DNA complexed with stearyl-poly(L-lysine)-low density lipoprotein (TerplexDNA). Three day left heart myocardial cell lysates produced 44571 ± 8730 RLU (RLU = total light units/mg protein) for the TerplexDNA luciferase rabbits versus 1638 ± 567 RLU for the naked luciferase rabbits (P = 0.002). Thirty days after injection, myocardial lysates produced 677 ± 52 RLU for the TerplexDNA luciferase hearts versus 18 ± 3 RLU for the naked luciferase hearts (P = 0.002). Histologic analysis of the hearts transfected with ␤-galactosid-
Introduction
Human gene therapy has become an area of intense research during the past decade. To date, most gene therapy has focused on gene delivery using viral vectors (retroviral or adenoviral) or nonviral vectors derived from polycationic elements. 1 Unfortunately, no single delivery system has proven to be ideal when considering their use in humans and the potential for side-effects. 2 The limitations of current therapy include the sideeffects of viral vectors, difficulty localizing the gene to the appropriate site, and limitations in transfection efficiency associated with polycationic vectors. 3 Further, human gene therapy using viral vectors has potential ill effects due to the virus itself. 4, 5 These include over-expression, activation of oncogenes, immunogenicity, and the random insertion pattern characteristic of many viruses. In addition, there is concern regarding the long-term effects of such constructs.
Despite the drawbacks of virus-mediated transfection, nonviral gene delivery systems have not been fully embraced, partly because of low transfection rates. 6, 7 Correspondence: SW Kim ade showed that TerplexDNA increased the area and depth of transfection compared with the naked plasmid DNA alone. The hearts of Sprague-Dawley rats were injected in a similar fashion and analyzed at 1, 3, 5, 10, 15, 25 and 30 days after injection. The naked luciferase injected hearts showed transient elevation of luciferase activity to day 5 but fell back to baseline levels after that time-point. The TerplexDNA luciferase injected hearts had significantly elevated luciferase activity to 30 days. The Terplex gene delivery system significantly augments myocardial transfection compared with a naked plasmid DNA system alone. The advantage in transfection efficiency appears to be related to the unique properties of the TerplexDNA carrier molecule. The TerplexDNA delivery system represents a novel means to augment transfection of the myocardium. Gene Therapy (2001) 8, 349-353.
While naked plasmid DNA has been successfully transfected into the myocardium via direct injection, its use has been limited by low gene transfection efficiency.
To address these issues, we developed a novel, nonvirus mediated DNA delivery system. 8, 9 This novel delivery vehicle is derived from stearyl-poly(L-lysine) (stearyl-PLL), low density lipoprotein (LDL) and plasmid DNA, and is generated through electrostatic and hydrophobic interactions between LDL, stearyl-PLL, and DNA. We refer to this carrier vehicle as TerplexDNA (Figure 1) .
We hypothesized that the TerplexDNA system would provide an improved means for delivering DNA to the myocardium. We conducted a series of experiments utilizing direct myocardial injection of this novel gene carrier to establish its efficiency using previously established protocols for gene delivery and detection.
10,11

Results
Rabbit left heart luciferase activity was significantly higher in the group injected with the Terplex + pCMVLuc versus naked pCMV-Luc (Figure 2 ). At 3 days, for rabbits injected with volumes of 1000 l, luciferase activity from the left ventricular cell lysate was 44571 ± 8730 RLU for the Terplex + pCMV-Luc animals versus 1638 ± 567 RLU for the naked pCMV-Luc animals (P = 0.002). Thirty days after 1000 l injections, luciferase activity was 677 ± 52 RLU for the Terplex + pCMV-Luc hearts versus 18 ± 3 RLU for the naked pCMV-Luc hearts (P = 0.002). In the 300 l volume, 3-day injection groups, the difference was not as large: 5880 ± 5091 RLU (Terplex + pCMV-Luc) versus 383 ± 218 RLU (pCMV-Luc), (P = 0.26). With the same amount of plasmid DNA (50 g), the gene transfer efficiency was dramatically enhanced with the increase of injectate volume (Figure 3 ), consistent with previous reports from other groups. 10, 11 Rat heart transfection was compared between the naked pCMV-Luc and Terplex + pCMV-Luc groups 1, 3, 5, 7, 10, 15, 25, and 30 days after injection ( Figure 4 ). The naked pCMV-Luc hearts showed a transient elevation in luciferase activity to day 5, peaking at 15210 ± 3111 RLU 3 days after injection. By day 7, the luciferase activity among the naked luciferase injected hearts had fallen back to baseline, day 0 levels. Meanwhile, the Terplex + pCMV-Luc hearts demonstrated significantly elevated transfection efficiency compared with the naked group at all time-points, peaking at 324 666 ± 88 008 RLU on day 3. Further, transfection efficiency in the TerplexDNA group remained significantly elevated to day 30 ( Figure 4) .
To evaluate the systemic distribution of the injected plasmid in the rabbit model, homogenates of the right heart, right lung, left lateral segment of liver, and kidney were assayed for luciferase activity. Figure 5 demonstrates the rabbit luciferase activity from these organs 3 days after injection in both the Terplex + pCMV-Luc and naked pCMV-Luc animals. Both groups demonstrate relatively minor systemic distribution compared with the direct injection site. Lung luciferase activity was significantly lower in the rabbits injected with the TerplexDNA system: 16.6 ± 3.9 RLU (Terplex + pCMV-Luc) versus 50.6 ± 18.2 RLU (pCMV-Luc), (P = 0.03). There was no statistical difference in luciferase activity in the other organs when comparing the pCMV-Luc and Terplex + pCMVLuc injected rabbits. Non-heart organ lysate luciferase activity was low in all groups, near the lower limit of assay detection.
Non-heart organ distribution of luciferase activity in the rat model was performed at each time-point to 30 days. The right lung, left lobe of the liver, right kidney, and spleen were obtained from each rat at the time of heart harvest and processed as previously described. Splenic luciferase activity was higher in the Terplex group compared with the naked group on days 7 and 15 (P = 0.02 and P = 0.003, respectively). Among all other organs, and at all time-points, there were no statistical differences in luciferase activity between the Terplex and naked injection groups. Again, all non-heart organ luciferase activity was near the lower limit of assay detection making any differences negligible.
Figure 4 Luciferase activity day 0 (D0) to day 30 (D30) after injection of the firefly luciferase gene into the apex of the heart of
Pattern and distribution of transfection was evaluated by histologic section of the injection site after transfection with either naked pCMV-LacZ or Terplex + pCMV-LacZ. Both groups were injected in a similar fashion, over 1 min, at equivalent depths. Figure 6 displays the gross appearance of the transfection site. The Terplex + CMVLacZ injected hearts demonstrated improved total area as well as depth of transfection by gross examination. Cytotoxicity and scarring was similar in both groups with fibroblasts scattered with myocytes near the injection site (not shown).
There were no untoward side-effects of the TerplexDNA injections demonstrated by cardiac monitoring during or after the injection. Transient premature contractions were noted but there were no episodes of sustained rhythm disturbance. Hearts appeared grossly similar at the time of excision with minor ecchymosis in both groups. One rabbit died 48 h after injection with naked luciferase DNA. 
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Figure 5 Genetic transfection in other organs are compared 3 days after injection of the firefly luciferase gene into the left ventricles of New Zealand white rabbits. Left ventricles were injected with naked pCMV-Luc or Terplex + pCMV-Luc. Lung luciferase (Luc) activity was lower in the animals injected with the TerplexDNA: 16.6 ± 3.9 RLU (Terplex + pCMV-Luc) versus 50.6 ± 18.2 RLU (pCMV-Luc), (P = 0.03). There was no statistical difference in luciferase activity in the other organs when comparing the naked pCMV-Luc to the Terplex + pCMV-Luc animals.
-galactosidase transfection is detected by incubation in X-gal (5-bromo-4-chloro-3-indolyl-␤-dgalactosidase) overnight at room temperature. Note the widespread transfection in the heart injected with TerplexDNA (Terplex + LacZ) compared with that of the naked plasmid LacZ alone.
Discussion
This study demonstrates that the TerplexDNA gene delivery system can be used to significantly augment the myocardial transfection rate in a live rabbit and rat model. The rate of transfection in the rabbit myocardium is 20-100-fold higher than that achieved using naked DNA. Compared with naked plasmid DNA, the Terplex system produces more widespread and uniform transfec-tion at the injection site as demonstrated by histologic staining. Further, in a rat model, we have demonstrated significantly improved transfection rates compared with naked plasmid injection. This difference is apparent up to 30 days after the injections.
The unique properties of the individual TerplexDNA components contribute to the transfection efficiency of the system as a whole. The PLL component complexes with the DNA, neutralizing electrostatic charges by interaction of the ⑀-amino groups with the negatively charged phosphate moieties on the DNA backbone. 8, 9 The stearyl groups participate in hydrophobic interactions with the core of the LDL molecule allowing integration into the molecule itself. 12 Incorporation of LDL into the polymer gene carrier likely enhances gene delivery through augmentation of the LDL receptor-mediated endocytosis pathway. 12 LDL receptors are present on the surface of many cell types including artery endothelial cells, 13, 14 myocytes, 15 and hepatocytes. 16 These receptors can be utilized as a means to augment endocytosis of the delivery vector and hence improve transfection.
The TerplexDNA gene carrier system has recently been characterized in vitro, as well as in vivo. Compared with DNA/Lipofectamine, the TerplexDNA system has shown a high gene transfer efficiency in a human hepatocyte line (HepG2), murine smooth muscle (A7R5) cell lines, 8, 9 and bovine aorta primary cell cultures, both vascular smooth muscle cells and endothelial cells. 12 Further, the TerplexDNA system has shown negligible cytotoxicity both in vitro and in vivo. 8, 9, 12, 17 Pharmacokinetic and biodistribution studies have shown that the TerplexDNA complex has improved circulation times as well as prolonged whole body retention compared with naked DNA. 17 Because Terplex can deliver DNA via a receptor-mediated endocytosis pathway, less toxicity is encountered compared with other polymer or liposome-mediated delivery systems. LDL mediated drug or gene delivery has been reported previously by our group, as well as others. 9, 18, 19 The advantage of Terplex LDL-mediated gene delivery in vivo may in part stem from its enhanced half-life, which, in turn increases time of exposure to cells with LDL receptors. The efficiency of myocardial transfection may be related to the interaction of the LDL apoprotein moiety and the myocardial Apo receptor making the myocardium particularly amenable to transfection.
Another advantage to the use of the TerplexDNA gene delivery system may be the result of the unique properties of the carrier vehicle itself. Since TerplexDNA contains non-immunologic components, it may be possible to administer genes in a repeated fashion. The TerplexDNA system has been used to deliver genes to various organs through repeat intravenous injections including liver (manuscript in preparation), and the arterial wall (manuscript in preparation). Hence, it may be possible to achieve effective transfection rates through repeat administration. The TerplexDNA system may therefore have applications in the treatment of heart disease in the clinical setting.
In conclusion, the TerplexDNA gene delivery system improves transfection efficiency in both the rabbit and rat myocardium compared with naked DNA. With its characteristics of minimal cytotoxicity and improved transfection efficiency, TerplexDNA is a viable alternative to adenoviral, liposomal, and naked DNA transfection systems. While more work must be done to establish its safety and document delivery of therapeutic genes, the TerplexDNA system is an efficient vector that may have potential application to the genetic therapy of clinical cardiovascular disease.
Materials and methods
To test the efficiency of the TerplexDNA system, the left ventricles of the hearts of New Zealand white rabbits were injected with the firefly luciferase or ␤-galactosidase gene either as naked plasmid DNA or complexed with Terplex. The anterior descending, circumflex, and posterolateral coronary arteries were used as landmarks for the left ventricular injection site in the rabbit model. All injections were performed over 1 min in a subepicardial location with a fixed amount of plasmid DNA (50 g) in injectate volumes of 300 l and 1000 l respectively.
The time course of Terplex-mediated transfection was further tested in a rat myocardial model. The apices of the hearts of Sprague-Dawley male rats, 400-500 g, were injected with 10 g of luciferase cDNA either as naked plasmid DNA or complexed with Terplex. Injections were performed over 20 s in injectate volumes of 150 l.
Plasmid carrying the firefly luciferase coding region under the control of the cytomegalovirus (CMV) immediate-early enhancer/promoter region and chicken ␤-globulin intron (pCMV-Luc), and plasmid coding for E. coli ␤-galactosidase, driven by the same promoter (pCMV-LacZ) were constructed. The luciferase and ␤-galactosidase genes were inserted into pCMV-Lei based on MluI and BamHI restriction sites. Plasmid DNA preparation was performed by double CsCl gradient purification. 20 Plasmid purity was determined spectrophotometrically at A260/A280 and was between 1.8 and 2.0. Purity of the plasmids was further verified by 0.8% agarose gel electrophoresis.
Transgene expression in the rabbit model was evaluated 3, 5 and 30 days after gene transfer by two methods: histochemical staining of excised, fixed myocardium for ␤-galactosidase and measurement of cell lysate luciferase activity. For ␤-galactosidase staining, hearts were excised, sectioned through the site of maximal staining into 2-mm slices, and fixed in 2% paraformaldehyde/0.2% glutaraldehyde for 1 h at room temperature. Sections were washed in PBS for 30 min using three changes of buffer. After the rinse in PBS, slices were incubated in X-gal (5-bromo-4chloro-3-indolyl-␤-d-galactosidase) for 12 h. The sections were again washed with PBS and embedded in paraffin. The paraffin processing was done through graded alcohols, but did not employ any further fixation with formalin. Sections were then counterstained with H&E or nuclear fast red for microscopic observation.
Measurement of luciferase activity was performed using a chemiluminescent assay (Luciferase Assay System; Promega, Madison, WI, USA). Tissue analysis in the rabbit model included the entire left ventricle, right ventricle, right lung, left lateral segment of the liver, and right kidney. In the rat model, tissue analysis included the apex of the heart, right lung, left lobe of the liver, right kidney, and the spleen. Organs were homogenized at 35 000 r.p.m. for 30 s in lysis buffer (1% Triton X-100, 100 mm K 3 PO 4 , 1 mm dithiothreitol, and 2 mm EDTA, pH 7.8). The homogenate was incubated on ice for 2 h and spun for 5 min to pellet debris. Twenty l aliquots of supernatant were mixed with 50 l of luciferase assay reagent at room temperature and read using a luminometer from Dynex Technologies (Chantilly, VA, USA). Light emission was measured in triplicate over 10 s. Control samples consisted of lysis buffer and luciferase assay reagent. Protein concentration was determined in each sample using the BCA protein assay (Pierce, Rockford, IL, USA) with bovine serum albumin used as a standard. Transfection efficiency was then standardized and expressed as luciferase activity normalized to the milligram protein content of homogenate, ie relative light units (RLU = total light units/ml homogenate/mg protein). This standardization was performed to account for any differences in tissue size.
Differences in luciferase activity between the pCMVLuc injected animals and Terplex + pCMV-Luc animals were analyzed using Statview software (Abacus Concepts, Berkeley, CA, USA). The data was analyzed using the unpaired t test. Differences were considered significant at P р 0.05.
